Download List of Abstracts

Joint Symposium
of the
Dana-Farber/Harvard Cancer Center
Programs in Breast and Gynecologic Cancers
March 4, 2016
GENETICS AND GENOMICS
1. Genome-scale Screening for New Oncogenes
Allison P Clark, Manish Neupane, Dave E Hill, Marc Vidal and Daniel P Silver
2. Integrated analysis of mRNA, copy number and proteomics profiles of TCGA
high-grade serous ovarian cancer reveals new markers of prognosis.
Aedin Culhane
3. The genomic evolution of endometrial carcinoma progression and
abdominopelvic metastasis.
William J. Gibson, Erling A. Hoivik, Mari K. Halle, Amaro Taylor-Weiner, Andrew D.
Cherniack, Anna Berg, Frederik Holst, Travis I. Zack, Henrica M. J. Werner, Kjersti M.
Staby, Mara Rosenberg, Ingunn M Stefansson, Kanthida Kusonmano, Aaron Chevalier,
Karen K. Mauland, Jone Trovik, Camilla Krakstad, Marios Giannakis, Eran Hodis,
Kathrine Woie, Line Bjorge, Olav K. Vintermyr, Jeremiah Wala, Michael S Lawrence,
Gad Getz , Scott L. Carter , Rameen Beroukhim , Helga B. Salvesen
4. Identification of subtype-specific gene regulation in high-grade serous ovarian
cancer
Kuijjer ML, Glass K, Quackenbush J
5. Feasibility and efficacy of a precision treatment approach for triple-negative
breast cancer in mouse models
Hui Liu, Charlie Murphy, Florian Karreth, Kang Kang Yang, Olivier Elemento, Gerburg
M. Wulf, Lewis C. Cantley
6. Analysis of Resistance to the Combination of a PI3K- and Parp-Inhibitor
Using a Genomic Sequencing Approach
Sheida Nabavi, Ashish Juvekar, Nicholas Wang, Lewis C. Cantley, and Gerburg
Wulf
7. Understanding the genomic underpinnings of breast cancer in young women
C Oh, N Wagle, E Morgan, B Larsen1, K Ruddy, T Cederroth, E Brachtel, L Schapira, SE
Come, V Borges, E Warner, E Winer, LC Collins and A Partridge
8. Epigenomic changes induced by PI3K/AKT inhibitors are mediated by the
dephosphorylation of the H3K4 demethylase KDM5A
Spangle, JM, Dreijerink, KM, Groner, AC, Cheng, H, Ohlson C, Reyes, J, Lin, CY, Bradner,
J,Zhao, JJ, Roberts, TM, and Brown, M.
9. An open-reading frame overexpression screen to identify genes mediating
cisplatin and paclitaxel response in high-grade serous ovarian cancer cell lines.
Elizabeth Stover, Cory Johanessen, Federica Piccioni, Mukta Bagul, Ursula Matulonis,
Levi Garraway
10. Mechanisms of resistance (MoR) to DNA damaging therapy in BRCA1/2deficient metastatic breast cancer (MBC)
Adrienne G. Waks, Ofir Cohen, Karla Helvie, Max Lloyd, Lori Marini, Coyin Oh, Nelly
Oliver, Neal I. Lindeman, Ursula Matulonis, Ian Krop, Levi A. Garraway, Eric P. Winer,
Nancy U. Lin, Nikhil Wagle
11. BCL6 and MYC cooperate to promote high grade serous ovarian cancer
Sarah R. Walker, Marieke Kuijjer, Yixi Zhang, John Quackenbush, and David A. Frank
12. CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Yubao Wang, Tinghu Zhang, Nicholas Kwiatkowski, Brian J. Abraham, Tong Ihn Lee,
Shaozhen Xie, Haluk Yuzugullu, Thanh Von, Heyuan Li, Ziao Lin, Daniel G. Stover,
Elgene Lim, Zhigang C. Wang, J. Dirk Iglehart, Richard A. Young, Nathanael S. Gray and
Jean J. Zhao
13. Chromosomal scars and response to PARP inhibitor-based therapy in ovarian
caner
Zhigang C. Wang, Nicolai Juul Birkbak, William T. Barry, Thomas M. Roberts, Eric P.
Winer, J Dirk Iglehart, Ursula A. Matulonis, and Joyce F. Liu
14. Tumor-Stroma Cross-Talk in High Grade Serous Ovarian Cancer
Oana A. Zeleznik, Shelley S. Tworoger, Aedin C. Culhane
CLINICAL AND TRANSLATIONAL STUDIES
15. The combination of bazedoxifene and palbociclib in the treatment of ER+
breast cancer
Macintosh Cornwell, Matthew Pun, Mai Nguyen, Gilles Buchwalter, Myles Brown,
Rinath Jeselsohn
16. Patterns of utilization of imaging and tumor markers (TM) among metastatic
breast cancer (MBC) patients (pts).
Antonio Di Meglio, Nancy U Lin, Rachel A Freedman, William T Barry, Eric P Winer,
Ines Vaz-Luis
17. ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Antiangiogenic Agents for Triple Negative Breast Cancer
Peng Guo, Jiang Yang, Marsha A. Moses and Debra T. Auguste
18. Design of effective combination therapies for high-grade serous ovarian cancer using
patient-derived xenograft models
Claudia Iavarone, Ioannis Zervantonakis, Laura Selfors, Hsing-Yu Chen, Sangeetha S.
Palakurthi, Joyce Liu, Ursula Matulonis, Ronny Drapkin, Gordon Mill, Joel Leverson, Deepak
Sampath, and Joan S. Brugge
19. In vivo synergism between PARP-inhibitor olaparib and HSP90-inhibitor
AT13387 in high grade serous ovarian cancer patient derived xenografts
Panagiotis A. Konstantinopoulos, Sangeetha Palakurthi, Qing Zeng, Shan Zhou, Joyce
F. Liu, Naveen Kommajosyula, Alan D. D’Andrea, Geoffrey I. Shapiro, Ursula A.
Matulonis
20. MicroRNA profiling to identify novel determinants of platinum resistance in
BRCA1/2-mutated high grade serous ovarian cancer
Khyati Meghani, Yizhou He, Elizabeth Swisher, Ursula Matulonis, Panagiotis A
Konstantinopoulos and Dipanjan Chowdhury
21. Orthotopic PDX models of HER2+ breast cancer brain metastases facilitate
discovery of a therapeutic strategy yielding durable remissions
Jing Ni, Shakti H. Ramkissoon, Shaozhen Xie, Shom Goel, Daniel G. Stover, Hanbing
Guo, Victor Luu, Eugenio Marco, Lori A. Ramkissoon, Yun Jee Kang, Marika Hayashi,
Quang-De Nguyen, Azra H. Ligon, Rose Du, Elizabeth B. Claus, Brian M. Alexander,
Guo-Cheng Yuan, Zhigang C. Wang, J. Dirk Iglehart, Ian E. Krop, Thomas M. Roberts,
Eric P. Winer, Nancy U. Lin, Keith L. Ligon, Jean J. Zhao
22. A Reversible Contraceptive that Protects the Ovarian Reserve During
Chemotherapy.
David Pépin, Motohiro Kano, Amanda Sosulski, Lihua Zhang, Fotini Nicolaou, Nicholas
Nagykery, Guangping Gao, Patricia K. Donahoe
23. Cost-effectiveness of the Oncotype Dx DCIS Score for Guiding Treatment of
Patients with Ductal Carcinoma In Situ
Ann C. Raldow, MD MPH, David Sher, MD MPH, Aileen B. Chen, MD MPP, Abram
Recht, MD, Rinaa S. Punglia, MD MPH
24. Immune Activation Signatures Identify a Subset of ER+ Breast Cancers with
Increased Pathologic Complete Response to Neoadjuvant Chemotherapy
Daniel G. Stover, Adrienne G. Waks, Sara M. Tolaney, Joan S. Brugge, Eric P. Winer,
and Laura M. Selfors
25. Immunogenicity of clear cell ovarian cancer: association with ARID1A loss,
microsatellite instability and endometriosis
Kyle C. Strickland, Brooke E. Howitt, Scott Rodig, Ursula A. Matulonis, Panagiotis A.
Konstantinopoulos
26. Nipple Changes During and After Pregnancy in Women who Have Undergone
Nipple Sparing Mastectomy
Rong Tang MD, Suzanne B. Coopey MD, Jennifer Plichta MD, Upahvan Rai, Amy S.
Colwell MD, Michele A. Gadd MD, Michelle C. Specht MD, William G. Austen, Jr. MD,
Barbara L. Smith MD, PhD
27. Factors associated with non-use of adjuvant trastuzumab in older patients with
HER2-positive breast cancer: a population-based study
Ines Vaz-Luis, Nancy U. Lin, Nancy L. Keating, William T. Barry, Joyce Lii, Harold J.
Burstein, Eric P. Winer, Rachel A. Freedman
28. Neutralization of BCL2/XL enhances the cytotoxicity of T-DM1 in vivo.
Jason J. Zoeller, Roderick T. Bronson, Deepak Sampath, Joel Leverson, Joan S. Brugge
RISK AND PREVENTION
29. QUALITY OF BREAST CANCER SCREENING IN BRAZIL: EXTERNAL ASSESSMENT
FOR IMPROVING ACCESS AND QUALITY PROGRAM
Mara Rejane Barroso Barcelos, Rita de Cássia Duarte Lima, Elaine Tomasi, Bruno
Nunes, Suele Manjourany Silva Duro, Malgorzata Chalupowski, Timothy Rebbeck,
Luiz Augusto Facchini
30. QUALITY OF CERVICAL CANCER SCREENING IN BRAZIL: EXTERNAL
ASSESSMENT OF IMPROVING ACCESS AND QUALITY PROGRAM
Mara Rejane Barroso Barcelos, Rita de Cássia Duarte Lima, Elaine Tomasi, Bruno
Nunes, Suele Manjourany Silva Duro, Malgorzata Chalupowski , Timothy Rebbeck,
Luiz Augusto Facchini
31. Caregiver burden and risk of epithelial ovarian cancer in the Nurses’ Health
Studies
Mollie E. Barnard, Tianyi Huang, Elizabeth M. Poole, Laura D. Kubzansky, Shelley S.
Tworoger
32. Air pollution at breast cancer diagnosis and survival from breast cancer
Natalie DuPre SM, Jaime E Hart ScD, Kimberly Bertrand ScD, Francine Laden ScD,
Rulla Tamimi ScD
33. Altered Progenitor Function and Breast Cancer Predisposition
Mihriban Karaayvaz, Kenneth Ross, Leif W. Ellisen
34. Breast cancer knowledge, behaviors, and preferences in Malawi: implications
for early detection
Racquel E. Kohler, PhD; Satish Gopal, MD MPH; Clara N. Lee, MD MPP; Bryan J.
Weiner, PhD; Bryce B. Reeve, PhD; Stephanie B. Wheeler, PhD MPH
35. Circulating Lipids and Mammographic Density
Sarah Lucht, Heather Eliassen, Rulla Tamimi
36. Pre- and post-diagnosis analgesic use and ovarian cancer survival
Melissa A. Merritt, Megan S. Rice, Shelley S. Tworoger, and Elizabeth M. Poole
37. Texture variation on a mammogram and risk of breast cancer
Megan Rice, Kimberly Bertrand, John Heine, Bernard Rosner, Rulla Tamimi
38. Single-cell analysis using CyTOF and DNA-Exchange-Imaging
Ron C.J. Schackmann, Jesse L. Silverberg, Sarit S. Agasti, Yu Wang, Peng Yin, Joan S.
Brugge
39. Mammography Decision-Making: Trends, Predictors and Effects of Provider
Communication in the Health Information National Trends Survey 2011-2014
Laura Spring, MD, Megan Marshall BS, and Erica T. Warner, ScD
40. Sleep duration and difficulty in relation to breast cancer survival:
Results from the Nurses’ Health Study
Claudia Trudel-Fitzgerald, PhD; Eric S. Zhou, PhD; Elizabeth M. Poole, PhD;
Xuehong Zhang, MD, ScD; Shelley S. Tworoger, PhD; Eva Schernhammer, MD, DrPH
41. Rotating Night Shift Work and Mammographic Breast Density in
Premenopausal and Postmenopausal Women in the Nurses’ Health Studies
Wegrzyn LR, Rosner BA, Tamimi RM, Schernhammer ES
TUMOR BIOLOGY
42. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple Negative Breast
Cancer
Adams BD, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Győrffy B,
Santarpia L, Pusztai L, Saltzman WM, and Slack FJ
43. Innovative therapeutic strategy to eradicate cancer stem cells and to prevent
OvCa recurrence
Chiara Bellio, Rosemary Foster, Whitfield B. Growdon and Bo R. Rueda
44. The dual roles of microRNA-200: From inclusion cyst formation to cell
migration.
Pui Wah Choi, Junzheng Yang, Wing Ping Fong, Ross S. Berkowitz, William R. Welch,
Gregory J. Goodall, Shu-Wing Ng
45. CDK4/6 inhibition sensitizes HER2-positive breast cancers to anti-HER2
therapy
Shom Goel, April C. Watt, Qi Wang, Sara M. Tolaney, Deborah A. Dillon, Wei Li, Haluk
Yuzugullu, X. Shirley Liu, Piotr Sicinski, Eric P. Winer, Ian E. Krop, Jean J. Zhao
46. Class IIa HDAC inhibition promotes an anti-tumor macrophage phenotype that
induces breast tumor regression and inhibits metastasis
Jennifer L. Guerriero, Alaba Sotayo, Holly E. Ponichtera, Alexandra Pourzia, Sara
Schad, Ruben D. Carrasco, Suzan Lazo, Roderick T. Bronson, Anthony Letai
47. Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of
Aldolase from the Actin cytoskeleton
Hai Hu, Ashish Juvekar, Costas A. Lyssiotis, Evan C. Lien, John G. Albeck, Doogie Oh,
Gopal Varma, Yin Pun Hung, Soumya Ullas, Josh Lauring, Pankaj Seth, Mark R.
Lundquist, Dean R. Tolan, Aaron K. Grant, Daniel J. Needleman, John M. Asara, Lewis
C. Cantley and Gerburg M. Wulf
48. A Role for FANCD2 in Fork Stability and Alternative End-Joining
Zeina Kais, Beatrice Rondinelli, Amie Holmes, Colin O'Leary, David Kozono, Alan D.
D'Andrea and Raphael Ceccaldi
49. Estrogen receptor-negative breast cancer cell lines exhibit hypersensitivity to
the CHK1 inhibitor LY2606368
Jean-Bernard Lazaro, Elizaveta Reznichenko, Kalindi Parmar, Geoffrey I. Shapiro,
Alan D. D’Andrea
50. MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism
which mimics the role of activated RAS in cancers
Manish Neupane, Allison P. Clark, Serena Landini, Nicolai J. Birkbak, Aron C. Eklund,
Elgene Lim, Aedin C. Culhane, William T. Barry, Steven E. Schumacher, Rameen
Beroukhim, Zoltan Szallasi, Marc Vidal, David E. Hill, Daniel P. Silver
51. Cellular Origin for Epithelial Ovarian Cancer
Eun-Sil Park and Zhe Li
52. Sentinel lymph node metastases in breast cancer: A contributor to distant
metastases?
Ethel R. Pereira, Dmitriy Kedrin, Dennis Jones, Elizabeth Beech, Alphonse G. Taghian
and Timothy P. Padera
53. Deciphering the alterations of the ER cistrome with the acquisition of
tamoxifen resistance
Matthew Pun, Macintosh Cornwell, Myles Brown, Rinath Jeselsohn
54. Treatment of ovarian cancer by targeting the tumor stem cell-associated
carbohydrate antigen sialyl Tn
K. Starbuck, D. Eavarone, J. Prendergast, A.P.G. da Silva, J. DeSander, J. Behrens2, B.
Rueda, R. Foster
55. The Jak/STAT3 signaling pathway promotes 3D growth of ovarian cancer
Sarah R. Walker, Yixi Zhang, Suhu Liu, and David A. Frank
56. BRCA1 suppresses tandem duplications at Tus/Ter-stalled replication forks.
Nicholas A. Willis, Richard L. Frock, Frederick W. Alt, Ralph Scully
57. Distinct EMT Programs Control Normal Stem Cells and Cancer Stem Cells of
Mammary Tissue
Xin Ye, Wai Leong Tam, Tsukasa Shibue, Yasemin Kaygusuz, Ferenc Reinhardt, and
Robert A. Weinberg1
58. Pinin Interacts with C-terminal Binding Proteins for RNA Alternative Splicing
and Epithelial Cell Identity of Human Ovarian Cancer Cells
Yanli Zhang, Jamie Sui-Lam Kwok, Pui-Wah Choi, Minghua Liu, Junzheng Yang, Margit
Singh, Shu-Kay Ng, William R. Welch, Michael G. Muto, Stephen KW Tsui, Stephen P.
Sugrue, Ross S. Berkowitz, and Shu-Wing Ng